Do Pharmaceutical Firms Invest More Heavily in Countries with Data Exclusivity?
Currents International Trade Law Journal, Summer 2013
21 Pages Posted: 4 May 2013 Last revised: 2 May 2019
Date Written: 2013
Countries may choose various methods of data protection in order to comply with the TRIPS Agreement. Policymakers should consider the effects of data exclusivity on prices and investment relative to other types of data protection. The data presented here suggest there is no relationship between whether or not a country has data exclusivity, and the amount of investment in the country by the pharmaceutical industry. On the other hand, empirical evidence in previous papers has shown that data exclusivity does drive prices higher.
Keywords: intellectual property, IP, pharmaceutical
JEL Classification: O31, O34, O38
Suggested Citation: Suggested Citation